MBX — Microbix Biosystems Share Price
0.000.00%
Last trade - 00:00- CA$49.36m
- CA$42.76m
- CA$25.39m
- 80
- 49
- 87
- 84
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 9.8 | ||
| PEG Ratio (f) | 0.46 | ||
| EPS Growth (f) | 27.01% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.71 | ||
| Price to Tang. Book | 1.99 | ||
| Price to Free Cashflow | 28.56 | ||
| Price to Sales | 2.14 | ||
| EV to EBITDA | 10.36 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 5.85% | ||
| Return on Equity | 6.85% | ||
| Operating Margin | 9% | ||
Financial Summary
| Year End 30th Sep | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 10.52 | 18.59 | 19.08 | 16.51 | 25.39 | 27 | 36.7 | 13.62% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | -42.11 | n/a | n/a | +17.19 | +33.33 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.
Directors
- Martin Marino NEC
- Cameron Groome PRE
- James Currie CFO (62)
- Philip Casselli SVP
- Mark Luscher SVP
- Peter Blecher IND
- Mark Cochran IND
- Vaughn Embro-Pantalony IND
- Anthony Giovinazzo IND
- Joseph Renner IND
- Last Annual
- September 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 3rd, 1978
- Public Since
- October 1st, 1992
- No. of Employees
- 69
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Toronto Stock Exchange
- Shares in Issue
- 141,031,735
- Address
- 265 Watline Avenue, MISSISSAUGA, L4Z 1P3
- Web
- https://microbix.com/
- Phone
- +1 9053618910
- Auditors
- Ernst & Young LLP
Upcoming Events for MBX
Q3 2025 Microbix Biosystems Inc Earnings Release
Similar to MBX
Appili Therapeutics
Toronto Stock Exchange
Avicanna
Toronto Stock Exchange
Briacell Therapeutics
Toronto Stock Exchange
Cardiol Therapeutics
Toronto Stock Exchange
COSCIENS Biopharma
Toronto Stock Exchange
FAQ
What is the Microbix Biosystems share price?
As of Today at 22:03 UTC, shares in Microbix Biosystems are trading at CA$0.35. This share price information is delayed by 15 minutes.
How has the Microbix Biosystems share price performed this year?
Shares in Microbix Biosystems last closed at CA$0.35 and the price had moved by +4.48% over the past 365 days. In terms of relative price strength the Microbix Biosystems share price has underperformed the Toronto Stock Exchange 300 Composite Index by -7.11% over the past year.
What are the analyst and broker recommendations for Microbix Biosystems?
The overall consensus recommendation for Microbix Biosystems is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Microbix Biosystems dividend yield?
Microbix Biosystems does not currently pay a dividend.
Does Microbix Biosystems pay a dividend?
Microbix Biosystems does not currently pay a dividend.
When does Microbix Biosystems next pay dividends?
Microbix Biosystems does not currently pay a dividend.
How do I buy Microbix Biosystems shares?
To buy shares in Microbix Biosystems you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Microbix Biosystems?
As of the previous close price of CA$0.35, shares in Microbix Biosystems had a market capitalisation of CA$49.36m.
Where are Microbix Biosystems shares listed?
Here are the trading details for Microbix Biosystems:
- Country of listing: Canada
- Exchange: TOR
- Ticker Symbol: MBX
What kind of share is Microbix Biosystems?
Based on an overall assessment of its quality, value and momentum Microbix Biosystems is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Microbix Biosystems share price forecast for 2025?
The analyst consensus target price for shares in Microbix Biosystems is CA$0.90. That is 157.14% above the last closing price of CA$0.35.
Analysts covering Microbix Biosystems currently have a consensus Earnings Per Share (EPS) forecast of CA$0.03 for the next financial year.
Find out moreWhat is the trend in the Microbix Biosystems share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Microbix Biosystems. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +7.06%.
As of the last closing price of CA$0.35, shares in Microbix Biosystems were trading -6.31% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Microbix Biosystems PE Ratio?
The Microbix Biosystems PE ratio based on its reported earnings over the past 12 months is 9.8. The shares last closed at CA$0.35.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Microbix Biosystems?
Microbix Biosystems' management team is headed by:
- Martin Marino - NEC
- Cameron Groome - PRE
- James Currie - CFO
- Philip Casselli - SVP
- Mark Luscher - SVP
- Peter Blecher - IND
- Mark Cochran - IND
- Vaughn Embro-Pantalony - IND
- Anthony Giovinazzo - IND
- Joseph Renner - IND